|
Video: What is a Stock Split?
|
|
Eyegate Pharmaceuticals is a clinical-stage pharmaceutical company focused on developing products for treating disorders of the eye. Co.'s key product in clinical development is the EyeGate Ocular Bandage Gel, a topically applied eye drop formulation of modified hyaluronic acid (HA). HA is a naturally occurring polymer that is used in various physiological processes, including wound healing, hydration, tissue homeostasis, and joint lubrication. Co. modifies the HA through chemical cross-linking, which allows it to adhere to the ocular surface providing protection and lubrication for the treatment of corneal wounds, defects, and epitheliopathies. According to our EYEG split history records, AB Corporate Bond Etf has had 1 split. | |
|
AB Corporate Bond Etf (EYEG) has 1 split in our EYEG split history database. The split for EYEG took place on August 30, 2019. This was a 1 for 15 reverse split, meaning for each 15 shares of EYEG owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 66.6666666666667 share position following the split.
When a company such as AB Corporate Bond Etf conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the EYEG split history from start to finish, an original position size of 1000 shares would have turned into 66.6666666666667 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into AB Corporate Bond Etf shares, starting with a $10,000 purchase of EYEG, presented on a split-history-adjusted basis factoring in the complete EYEG split history.
Growth of $10,000.00
With Dividends Reinvested
|
Start date: |
12/13/2023 |
|
End date: |
01/16/2025 |
|
Start price/share: |
$35.59 |
|
End price/share: |
$34.98 |
|
Starting shares: |
280.99 |
|
Ending shares: |
289.47 |
|
Dividends reinvested/share: |
$1.07 |
|
Total return: |
1.27% |
|
Average Annual Total Return: |
1.16% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$10,127.19 |
|
Years: |
1.10 |
|
|
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
12/13/2023 |
|
End date: |
01/16/2025 |
|
Start price/share: |
$35.59 |
|
End price/share: |
$34.98 |
|
Dividends collected/share: |
$1.07 |
|
Total return: |
1.30% |
|
Average Annual Total Return: |
1.19% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$10,130.49 |
|
Years: |
1.10 |
|
|
|
Date |
Ratio |
08/30/2019 | 1 for 15 |
|
|